{"id":26532,"date":"2024-01-31T11:32:17","date_gmt":"2024-01-31T11:32:17","guid":{"rendered":"https:\/\/ibima.eu\/?post_type=project&#038;p=26532"},"modified":"2025-11-25T13:09:16","modified_gmt":"2025-11-25T13:09:16","slug":"b-05","status":"publish","type":"project","link":"https:\/\/ibima.eu\/en\/project\/b-05\/","title":{"rendered":"B-05"},"content":{"rendered":"\n[et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2023\/04\/FotoWeb-min-1000&#215;500-1.jpg\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb250px||30px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|700|||||||\u00bb header_text_align=\u00bbcenter\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb40px\u00bb header_2_font=\u00bbPoppins|700|||||||\u00bb header_2_text_color=\u00bb#FFFFFF\u00bb header_2_font_size=\u00bb46px\u00bb global_colors_info=\u00bb{}\u00bb]<h1>Investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9tica<\/h1>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#235b78&#8243; custom_padding=\u00bb30px||30px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb header_3_font=\u00bbPoppins|700|||||||\u00bb header_3_text_color=\u00bb#FFFFFF\u00bb header_3_font_size=\u00bb34px\u00bb global_colors_info=\u00bb{}\u00bb]<h3>Lineas de Investigaci\u00f3n<\/h3>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#d3d6dd\u00bb custom_margin=\u00bb||||true|false\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb2&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb70%\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#235b78&#8243; text_font_size=\u00bb16px\u00bb text_line_height=\u00bb2.1em\u00bb global_colors_info=\u00bb{}\u00bb]<p><span style=\"color: #43a5d3;\"><strong>01.<\/strong><\/span>Oncolog\u00eda y Hematolog\u00eda<br \/><span style=\"color: #43a5d3;\"><strong>02.<\/strong><\/span>Inmunoterapia del C\u00e1ncer<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb2_3,1_3&#8243; use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb2&#8243; make_equal=\u00bbon\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb90%\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb2_3&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_tabs active_tab_background_color=\u00bb#105e7c\u00bb inactive_tab_background_color=\u00bb#41a7d4&#8243; active_tab_text_color=\u00bb#FFFFFF\u00bb _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb tab_text_color=\u00bb#FFFFFF\u00bb tab_font_size=\u00bb12px\u00bb width=\u00bb90%\u00bb border_color_all=\u00bb#41a7d4&#8243; global_colors_info=\u00bb{}\u00bb][et_pb_tab title=\u00bbProyectos de investigaci\u00f3n\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"26527\"][\/et_pb_section]\n<div id=\"gtx-trans\" style=\"position: absolute; left: 201px; top: 38px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>[\/et_pb_tab][et_pb_tab title=\u00bbEstudios cl\u00ednicos\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"26523\"][\/et_pb_section][\/et_pb_tab][et_pb_tab title=\u00bbPublicaciones cient\u00edficas\u00bb _builder_version=\u00bb4.25.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"26525\"][\/et_pb_section][\/et_pb_tab][et_pb_tab title=\u00bbOfertas tecnol\u00f3gicas\u00bb _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"38410\"][\/et_pb_section][\/et_pb_tab][et_pb_tab title=\u00bbRegistros de propiedad industrial\u00bb _builder_version=\u00bb4.25.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb border_width_left=\u00bb1px\u00bb border_color_left=\u00bbrgba(67,165,211,0.32)\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_blurb title=\u00bbMiembros\u00bb use_icon=\u00bbon\u00bb font_icon=\u00bb&#xf0c0;||fa||900&#8243; icon_color=\u00bb#43a5d3&#8243; icon_placement=\u00bbleft\u00bb _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#235b78&#8243; header_font_size=\u00bb22px\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb||||false|false\u00bb custom_padding=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blurb][et_pb_divider color=\u00bb#43a5d3&#8243; divider_weight=\u00bb2px\u00bb _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb70%\u00bb custom_padding=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_divider][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigador Responsable\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blurb title=\u00bbAntonio Rueda Dom\u00ednguez\u00bb image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2024\/02\/CIMO-2-Antonio-Rueda.png\u00bb icon_placement=\u00bbleft\u00bb image_icon_width=\u00bb71px\u00bb content_max_width=\u00bb558px\u00bb _builder_version=\u00bb4.24.1&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_color=\u00bb#24a8d7&#8243; body_link_text_color=\u00bb#919191&#8243; custom_padding=\u00bb|||80px|false|false\u00bb hover_enabled=\u00bb0&#8243; border_radii_image=\u00bbon|25%|25%|25%|25%\u00bb global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<p><strong>Correo electr\u00f3nico: <a href=\"mailto:rueda.dominguez@gmail.com\">rueda.dominguez@gmail.com<\/a> <\/strong><br \/><a href=\"https:\/\/orcid.org\/0000-0001-5890-0149\"><strong>ORCID<\/strong><\/a><br \/><a href=\"https:\/\/www.scopus.com\/authid\/detail.uri?authorId=7007114662\"><strong>SCOPUS<\/strong><\/a><\/p>[\/et_pb_blurb][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbCo-Investigadora Responsable\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][et_pb_blurb title=\u00bbMar\u00eda Isabel Barrag\u00e1n Mallofret\u00bb image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2024\/02\/CIMO2-COIR-M.Isabel.png\u00bb icon_placement=\u00bbleft\u00bb image_icon_width=\u00bb71px\u00bb _builder_version=\u00bb4.24.1&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_color=\u00bb#24a8d7&#8243; body_link_text_color=\u00bb#919191&#8243; custom_padding=\u00bb|||80px|false|false\u00bb border_radii_image=\u00bbon|25%|25%|25%|25%\u00bb global_colors_info=\u00bb{}\u00bb]<p><strong>Correo electr\u00f3nico: <a href=\"mailto:isabel.barragan.mallofret@gmail.com\">isabel.barragan.mallofret@gmail.com<\/a> <\/strong><br \/><a href=\"https:\/\/orcid.org\/0000-0002-8586-6502\"><strong>ORCID<\/strong><\/a><br \/><a href=\"https:\/\/www.scopus.com\/authid\/detail.uri?authorId=10042822900\"><strong>SCOPUS<\/strong><\/a><\/p>[\/et_pb_blurb][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigador\/a S\u00e9nior\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb1875&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigador\/a Asistencial Colaborador\/a\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb1872&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigadores\/as posdoctorales y\/o junior\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb1876&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigadores\/as predoctorales y\/o en formaci\u00f3n\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb1874&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbPersonal T\u00e9cnico\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb1871&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"<p>Investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9ticaLineas de Investigaci\u00f3n01.Oncolog\u00eda y Hematolog\u00eda02.Inmunoterapia del C\u00e1ncer<div class=\"et_pb_with_border et_pb_module et_pb_blog_0 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix \">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"et_pb_salvattore_content\" data-columns>\n\t\t\t<article id=\"post-42629\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_0 post-42629 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/gem23_01-ex-vivo-characterization-of-the-mechanisms-associated-with-abscopal-response-2\/\">GEM23_01 \u201cEx vivo characterization of the mechanisms associated with Abscopal Response\u201d.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>MARIA ISABEL BARRAG\u00c1N MALLOFRET &#8211; MIGUEL ANGEL BERCIANO GUERRERO &#8211; LOCAL &#8211; GRUPO ESPA\u00d1OL MULTIDISCIPLINAR DE MELANOMA (GEM) &#8211; 2023<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56449\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_1 post-56449 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/cns2023-145629-pi-ayuda-adiccional-multi-modal-and-multi-scale-modeling-based-on-artificial-intelligence-pathways-and-spatial-transcriptomics-to-reveal-lung-cancer-distant-relapse-predictors-maps-lun\/\">CNS2023-145629-PI Ayuda Adiccional Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial Transcriptomics to reveal Lung Cancer Distant Relapse predictors (MAPS-LUNG)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>MARIA ISABEL BARRAG\u00c1N MALLOFRET &#8211;  &#8211; NACIONAL &#8211; AGENCIA ESTATAL DE INVESTIGACI\u00d3N &#8211; 2023<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56478\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_2 post-56478 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/dts23-00114-epipredict-desarrollo-de-un-panel-de-marcadores-epigeneticos-en-biopsia-liquida-para-la-prediccion-de-respuesta-y-pronostico-en-nuevas-estrategias-inmunoterapicas\/\">DTS23-00114 EPIPREDICT: Desarrollo de un panel de marcadores epigen\u00e9ticos en biopsia l\u00edquida para la predicci\u00f3n de respuesta y pron\u00f3stico en nuevas estrategias inmunoter\u00e1picas<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>MARIA ISABEL BARRAG\u00c1N MALLOFRET &#8211;  &#8211; NACIONAL &#8211; INSTITUTO DE SALUD CARLOS III &#8211; 2023<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56514\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_3 post-56514 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/gld23-00137-maps-lung-multi-modal-and-multi-scale-modeling-based-on-artificial-intelligence-pathways-and-spatial-sequencing-to-reveal-lung-cancer-metastatic-landscape\/\">GLD23-00137 \u201cMAPS-LUNG: Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial sequencing to reveal Lung Cancer Metastatic Landscape\u201d<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211;  &#8211; NACIONAL &#8211; GILEAD SCIENCES, S.L.U &#8211; 2023<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56624\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_4 post-56624 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/pryes247250barr-descifrando-las-firmas-epigeneticas-de-la-respuesta-abscopal-para-guiar-la-inmunoterapia-de-precision-epi-sabr\/\">PRYES247250BARR Descifrando las firmas epigen\u00e9ticas de la respuesta abscopal para guiar la inmunoterapia de precisi\u00f3n  (EPI-SABR)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>MARIA ISABEL BARRAG\u00c1N MALLOFRET &#8211;  &#8211; NACIONAL &#8211; ASOCIACI\u00d3N ESPA\u00d1OLA CONTRA EL C\u00c1NCER &#8211; 2023<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-19101\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_5 post-19101 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/proy_excel_01002-farmacogenomica-de-precision-aplicada-al-tratamiento-de-inmunoterapia-en-cancer-de-pulmon-y-cabeza-y-cuello\/\">Proy_Excel_01002 Farmacogenomica de precisi\u00f3n aplicada al tratamiento de inmunoterapia en C\u00e1ncer de pulm\u00f3n y Cabeza y Cuello.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>FRANCISCO JAVIER OLIVER MARTOS &#8211; ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; REGIONAL &#8211; CONSEJER\u00cdA DE UNIVERSIDAD, INVESTIGACI\u00d3N E INNOVACI\u00d3N &#8211; 2022<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56587\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_6 post-56587 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/pi22-01816-biomarcadores-de-resistencia-a-la-inmunoterapia-integrando-efecto-abscopal-y-epigenetica-en-una-estrategia-de-medicina-de-precision-no-invasiva\/\">PI22-01816 Biomarcadores de resistencia a la inmunoterapia: integrando Efecto Abscopal y epigen\u00e9tica en una estrategia de medicina de precisi\u00f3n no invasiva<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>MARIA ISABEL BARRAG\u00c1N MALLOFRET &#8211; MANUEL COBO DOLS &#8211; NACIONAL &#8211; INSTITUTO DE SALUD CARLOS III &#8211; 2022<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-18988\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_7 post-18988 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/cpc21201_seom-deteccion-temprana-de-metastasis-hepaticas-en-cancer-de-mama-basado-en-el-estudio-de-patrones-de-metilacion-e-hidroximetilacion-en-el-adn-libre-circulante-en-sangre\/\">CPC21201_SEOM Detecci\u00f3n temprana de met\u00e1stasis hep\u00e1ticas en c\u00e1ncer de mama basado en el estudio de patrones de metilaci\u00f3n e hidroximetilaci\u00f3n en el adn libre circulante en sangre<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>MARIA ISABEL BARRAG\u00c1N MALLOFRET &#8211;  &#8211; NACIONAL &#8211; SOCIEDAD ESPA\u00d1OLA DE ONCOLOG\u00cdA M\u00c9DICA &#8211; 2021<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-18989\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_8 post-18989 post type-post status-publish format-standard hentry category-proyectos category-proyectos-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/cpc21210-seom-micro-rnas-como-huellas-en-la-caracterizacion-y-deteccion-precoz-del-efecto-de-cancerizacion-de-campo-en-el-carcinoma-escamoso-de-cavidad-oral\/\">CPC21210-SEOM Micro- RNAs como huellas en la caracterizaci\u00f3n y detecci\u00f3n precoz del efecto de cancerizaci\u00f3n de campo en el carcinoma escamoso de cavidad oral.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ELISABETH PEREZ RUIZ &#8211;  &#8211; NACIONAL &#8211; SOCIEDAD ESPA\u00d1OLA DE ONCOLOG\u00cdA M\u00c9DICA &#8211; 2021<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div><div><div class=\"pagination clearfix\">\n\t<div class=\"alignleft\"><\/div>\n\t<div class=\"alignright\"><\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div> <div class=\"et_pb_with_border et_pb_module et_pb_blog_1 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix \">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"et_pb_salvattore_content\" data-columns>\n\t\t\t<article id=\"post-56350\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_0 post-56350 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/the-aim-hn-and-seq-hn-study-a-2-cohort-non-comparative-pivotal-study-evaluating-the-afficacy-of-tipifarnib-in-patients-with-head-and-neck-squamous-cell-carcinoma-hnscc-with-hras-mutations-aim-hn\/\">The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Afficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ELISABETH PEREZ RUIZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; <\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56306\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_1 post-56306 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/registro-para-recoger-datos-de-las-caracteristicas-y-resultados-de-pacientes-con-tumores-solidos-a-los-que-se-realizo-una-prueba-de-secuenciacion-de-nueva-generacion-wayfind-r\/\">Registro para recoger datos de las caracter\u00edsticas y resultados de pacientes con Tumores S\u00f3lidos a los que se realiz\u00f3 una prueba de secuenciaci\u00f3n de nueva generaci\u00f3n (WAYFIND-R).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE CARLOS BEN\u00cdTEZ MONTA\u00d1\u00c9S &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; No aplica &#8211; ROCHE FARMA, S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-33067\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_2 post-33067 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/nivolumab-e-ipilimumab-mas-dos-ciclos-de-quimioterapia-basada-en-platino-como-tratamiento-de-primera-linea-para-pacientes-con-cancer-de-pulmon-no-microcitico-cpnm-estadio-iv-o-recurrente-con-metasta\/\">Nivolumab e Ipilimumab m\u00e1s dos ciclos de quimioterapia basada en platino como tratamiento de primera l\u00ednea para pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) estadio IV o recurrente con met\u00e1stasis cerebrales sincr\u00f3nicas. (NIVIPI-Brain)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ALEJANDRA CANTERO GONZ\u00c1LEZ &#8211; ENSAYO CLINICO INDEPENDIENTE &#8211; II &#8211; FUNDACI\u00d3N GECP<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-32958\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_3 post-32958 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-observacional-cuyo-objetivo-es-evaluar-la-proporcion-de-cancer-de-cabeza-y-cuello-head-and-neck-cancers-hnc-asociado-al-virus-del-papiloma-humano-vph-estudio-broaden\/\">Estudio observacional, cuyo objetivo es evaluar la proporci\u00f3n de c\u00e1ncer de cabeza y cuello (head and neck cancers, HNC) asociado al virus del papiloma humano (VPH), Estudio BROADEN.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ESTUDIO NO POSAUTORIZACION &#8211; No aplica &#8211; IQVIA INFORMATION S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-32869\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_4 post-32869 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-multicentrico-controlado-aleatorizado-y-abierto-sobre-la-eficacia-del-tratamiento-intratumoral-neoadyuvante-con-daromun-l19il2-l19tnf-seguido-de-cirugia-y-una-terapia-adyuvante-frente-a-c\/\">Estudio multic\u00e9ntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirug\u00eda y una terapia adyuvante frente a cirug\u00eda y una terapia adyuvante en pacientes con melanoma en estadio IIIB\/C<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ELISABETH PEREZ RUIZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; PHILOGEN S.P.A<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55899\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_5 post-55899 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-fase-i-ii-abierto-para-evaluar-la-seguridad-farmacocinetica-y-actividad-antitumoral-preliminar-de-ro7227166-ligando-4-1bb-dirigido-contra-cd19-en-combinacion-con-obinutuzumab-y-con-glofitam\/\">ESTUDIO FASE I\/II ABIERTO PARA EVALUAR LA SEGURIDAD, FARMACOCIN\u00c9TICA Y ACTIVIDAD ANTITUMORAL PRELIMINAR DE RO7227166 (LIGANDO 4-1BB DIRIGIDO CONTRA CD19) EN COMBINACI\u00d3N CON OBINUTUZUMAB Y CON GLOFITAMAB DESPU\u00c9S DE UNA DOSIS DE PRETRATAMIENTO CON OBINUTUZUMAB, EN PACIENTES CON LINFOMA NO HODGKIN DE LINFOCITOS B RECIDIVANTE\/REFRACTARIO<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; I &#8211; ROCHE FARMA, S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-32811\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_6 post-32811 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-fase-i-multicentrico-abierto-de-busqueda-de-dosis-de-cc-96673-en-sujetos-con-linfoma-no-hodgkin-en-recaida-o-refractario\/\">Estudio Fase I, multic\u00e9ntrico, abierto, de b\u00fasqueda de dosis de CC-96673 en sujetos con linfoma no Hodgkin en reca\u00edda o refractario<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; I &#8211; CELGENE CORPORATION<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55883\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_7 post-55883 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-fase-1b-2-de-bms-986442-en-combinacion-con-nivolumab-o-nivolumab-y-quimioterapias-en-participantes-con-tumores-solidos-avanzados-y-cancer-de-pulmon-no-microcitico\/\">Estudio fase 1b\/2 de BMS-986442 en combinaci\u00f3n con nivolumab o nivolumab y quimioterapias en participantes con tumores s\u00f3lidos avanzados y c\u00e1ncer de pulm\u00f3n no microc\u00edtico.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ALEJANDRA CANTERO GONZ\u00c1LEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55875\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_8 post-55875 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-fase-1-multicentrico-abierto-de-busqueda-de-dosis-para-evaluar-la-seguridad-tolerabilidad-farmacocinetica-farmacodinamia-y-eficacia-preliminar-de-bms-986458-en-monoterapia-y-en-combina\/\">Estudio fase 1, multic\u00e9ntrico, abierto, de b\u00fasqueda de dosis, para evaluar la seguridad, tolerabilidad, farmacocin\u00e9tica, farmacodinamia y eficacia preliminar de BMS-986458, en monoterapia y en combinaci\u00f3n con agentes antilinfoma, en participantes con linfomas no Hodgkin en reca\u00edda\/refractarios (LNH R\/R).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; I &#8211; BRISTOL -MYERS SQUIBB SERVICES UNLIMITED COMPANY<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-32791\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_9 post-32791 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-fase-1-multicentrico-abierto-para-determinar-la-seguridad-farmacocinetica-y-eficacia-preliminar-de-una-molecula-pequena-cc-99282-disponible-para-administracion-oral-en-monoterapia-y-en-co\/\">Estudio Fase 1, multic\u00e9ntrico, abierto para determinar la seguridad, farmacocin\u00e9tica y eficacia preliminar de una mol\u00e9cula peque\u00f1a, CC-99282, disponible para administraci\u00f3n oral en monoterapia y en combinaci\u00f3n con rituximab en sujetos con linfoma no Hodgkin en reca\u00edda o refractario (LNH R\/R)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; I &#8211; CELGENE S.L.U.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-32769\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_10 post-32769 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-iii-aleatorizado-doble-ciego-y-controlado-con-placebo-de-debio-1143-en-combinacion-con-quimioterapia-con-un-derivado-del-platino-y-radioterapia-de-intensidad-modulada-con-fraccionami\/\">Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de Debio 1143 en combinaci\u00f3n con quimioterapia con un derivado del platino y radioterapia de intensidad modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimiorradioterapia definitiva (TrilynX).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; DEBIOPHARM INTERNATIONAL S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-32768\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_11 post-32768 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-iii-aleatorizado-doble-ciego-sobre-los-efectos-de-encorafenib-y-binimetinib-mas-pembrolizumab-frente-a-placebo-mas-pembrolizumab-en-pacientes-con-diagnostico-de-melanoma-metastasico\/\">Estudio en Fase III, aleatorizado, doble ciego sobre los efectos de Encorafenib y Binimetinib m\u00e1s Pembrolizumab frente a placebo m\u00e1s Pembrolizumab en pacientes con diagn\u00f3stico de melanoma metast\u00e1sico o melanoma localmente avanzado irresecable con mutaci\u00f3n V600E\/K en Braf positiva.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ELISABETH PEREZ RUIZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; PFIZER, S.L.U.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55829\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_12 post-55829 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-iii-abierto-y-aleatorizado-de-loxo-305-en-comparacion-con-un-inhibidor-de-tirosina-cinasa-de-bruton-btk-por-sus-siglas-en-ingles-a-elegir-por-el-investigador-en-pacientes-con-lin\/\">Estudio en fase III, abierto y aleatorizado, de LOXO-305 en comparaci\u00f3n con un inhibidor de tirosina cinasa de Bruton (BTK, por sus siglas en ingl\u00e9s) a elegir por el investigador, en pacientes con linfoma de c\u00e9lulas del manto tratados previamente y sin tratamiento previo con inhibidoresde BTK (BRUIN MCL-321).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; IQVIA RDS SPAIN SL<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55827\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_13 post-55827 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-iii-abierto-y-aleatorizado-para-comparar-la-eficacia-y-la-seguridad-de-odronextamab-regn1979-un-anticuerpo-biespecifico-anti-cd20-y-anti-cd3-frente-al-tratamiento-elegido-por-el-i\/\">Estudio en Fase III, abierto y aleatorizado para comparar la eficacia y la seguridad de Odronextamab (REGN1979), un anticuerpo biespec\u00edfico ANTI-CD20 y ANTI-CD3, frente al tratamiento elegido por el investigador en participantes con Linfoma Folicular sin tratamiento previo (OLYMPIA-1).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; ICON CLINICAL RESEARCH LTD<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55808\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_14 post-55808 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-multicentrico-de-varios-grupos-abierto-y-de-prueba-de-concepto-de-patritumab-deruxtecan-her3-dxd-u3-1402-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos-he\/\">Estudio en fase II, multic\u00e9ntrico, de varios grupos, abierto y de prueba de concepto de patritumab deruxtec\u00e1n (HER3-DXd; U3-1402) en sujetos con tumores s\u00f3lidos localmente avanzados o metast\u00e1sicos (HERTHENA-PanTumor01).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ELISABETH PEREZ RUIZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; IQVIA RDS SPAIN SL<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-41823\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_15 post-41823 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-aleatorizado-doble-ciego-y-multicentrico-de-retifanlimab-en-combinacion-con-incagn02385-anti-lag-3-e-incagn02390-anti-tim-3-como-tratamiento-de-primera-linea-en-participantes\/\">Estudio en fase II, aleatorizado, doble ciego y multic\u00e9ntrico de retifanlimab en combinaci\u00f3n con INCAGN02385 (anti-LAG-3) e INCAGN02390 (anti-TIM-3) como tratamiento de primera l\u00ednea en participantes con carcinoma escamoso de cabeza y cuello metast\u00e1sico\/recidivante positivo para PD-L1 (CPS =1).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ELISABETH PEREZ RUIZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; II &#8211; Incyte Biosciences Distribution B.V.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-32724\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_16 post-32724 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-de-alx148-en-combinacion-con-pembrolizumab-y-quimioterapia-en-pacientes-con-carcinoma-de-celulas-escamosas-de-cabeza-y-cuello-avanzado-aspen-04\/\">Estudio en fase II de ALX148 en combinaci\u00f3n con pembrolizumab y quimioterapia en pacientes con carcinoma de c\u00e9lulas escamosas de cabeza y cuello avanzado (ASPEN-04)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; II &#8211; IQVIA BIOTECH<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55789\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_17 post-55789 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-de-alx148-en-combinacion-con-pembrolizumab-en-pacientes-con-carcinoma-de-celulas-escamosas-de-cabeza-y-cuello-avanzado-aspen-03\/\">Estudio en Fase II de ALX148 en combinaci\u00f3n con PEMBROLIZUMAB en pacientes con carcinoma de c\u00e9lulas escamosas de cabeza y cuello avanzado (ASPEN-03).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ANTONIO RUEDA DOM\u00cdNGUEZ &#8211; ENSAYO CLINICO COMERCIAL &#8211; II &#8211; IQVIA RDS SPAIN SL<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-41588\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_18 post-41588 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-abierto-y-aleatorizado-de-morab-202-farletuzumab-ecteribulina-un-conjugado-de-anticuerpo-y-farmaco-dirigido-al-receptor-a-de-folato-en-participantes-con-adenocarcinoma-ac-de-p\/\">Estudio en fase II abierto y aleatorizado de MORAb-202 (farletuzumab ecteribulina), un conjugado de anticuerpo y f\u00e1rmaco dirigido al receptor a de folato, en participantes con adenocarcinoma (AC) de pulm\u00f3n no microc\u00edtico (ACPNM) metast\u00e1sico despu\u00e9s de haber progresado con tratamientos anteriores<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE CARLOS BEN\u00cdTEZ MONTA\u00d1\u00c9S &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; BRISTOL-MYERS SQUIBB, S.A.U.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55783\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_19 post-55783 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-b-05-ensayos-clinicos\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-ib-ii-abierto-y-de-multiples-cohortes-para-evaluar-la-seguridad-la-eficacia-y-la-dosis-optima-de-abbv-400-en-combinacion-con-budigalimab-en-el-cpnm-no-epidermoide-avanzado-o-metastas\/\">Estudio en fase Ib\/II, abierto y de m\u00faltiples cohortes para evaluar la seguridad, la eficacia y la dosis \u00f3ptima de ABBV-400 en combinaci\u00f3n con budigalimab en el CPNM no epidermoide avanzado o metast\u00e1sico sin tratamiento previo en caso de enfermedad avanzada y sin variaciones gen\u00f3micas accionables (AndroMETa-Lung-536).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE CARLOS BEN\u00cdTEZ MONTA\u00d1\u00c9S &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; ABBVIE DEUTSCHLAND GMBH &#038; CON K. G<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div><div><div class=\"pagination clearfix\">\n\t<div class=\"alignleft\"><a href=\"https:\/\/ibima.eu\/wp-json\/wp\/v2\/project\/26532\/page\/2\/?et_blog\" >&laquo; Older Entries<\/a><\/div>\n\t<div class=\"alignright\"><\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div><div class=\"et_pb_with_border et_pb_module et_pb_blog_2 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix \">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"et_pb_salvattore_content\" data-columns>\n\t\t\t<article id=\"post-50236\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_0 post-50236 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/first-hospital-contact-via-the-emergency-department-is-an-independent-predictor-of-overall-survival-and-disease-free-survival-in-patients-with-colorectal-cancer-6\/\">.First hospital contact via the Emergency Department is an independent predictor of overall survival and disease-free survival in patients with colorectal cancer<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Tellez, Teresa; Garcia-Aranda, Marilina; Zarcos-Pedrinaci, Irene; Rivas-Ruiz, Francisco; Perez-Ruiz, Elisabeth; del Carmen Padilla-Ruiz, Maria; Luisa Bare, Maria; Morales-Suarez-Varela, Manuela; Rueda, Antonio; Alcaide, Julia; Redondo, Maximino &#8211; 2019 &#8211; 10.17235\/reed.2019.5777\/2018<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-50228\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_1 post-50228 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/genetic-and-epigenetic-biomarkers-of-immune-checkpoint-blockade-response-4\/\">Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response,<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Xiao, QY; Nobre, A; Pineiro, P; Berciano-Guerrero, MA; Alba, E; Cobo, M; Lauschke, VM; Barragan, I &#8211; 2020<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-50225\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_2 post-50225 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/association-of-cerna-dysregulation-with-clinical-response-to-immunotherapy-in-cutaneous-melanoma-cm_\/\">Association of ceRNA dysregulation with clinical Response to Immunotherapy in cutaneous melanoma (CM)_<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Javier Oliver,\u00a0Juan Luis Onieva,\u00a0Maria Garrido-Barros,\u00a0Alicia Garrido-Aranda,\u00a0Vanessa De Luque,\u00a0Martina Alvarez,\u00a0Alfonso Sanchez,\u00a0Elisabeth Perez,\u00a0Patricia Chaves,\u00a0Maria Jose Lozano,\u00a0Miguel Berciano,\u00a0Manolo Cobo,\u00a0Emilio Alba,\u00a0Antonio Rueda,\u00a0Isabel Barragan &#8211; 2022 &#8211; 10.1158\/1538-7445.am2022-1538<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-50211\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_3 post-50211 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/t-cell-changes-induced-by-desensitisation-to-braf-inhibitors-in-two-patients-with-dress-2\/\">T-cell changes induced by desensitisation to BRAF inhibitors in two patients with DRESS<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Salas M ;Berciano-Guerrero MA ;Palomares F ;Rueda A ;Fernandez TD ;Mayorga C ;Torres MJ &#8211; 2021 &#8211; 10.1111\/all.14807;33682162<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52158\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_4 post-52158 post type-post status-publish format-standard hentry category-publicaciones-b-01 category-publicaciones-b-05 category-publicaciones-be-17\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/novel-blood-biomarkers-for-response-prediction-and-monitoring-of-stereotactic-ablative-radiotherapy-and-immunotherapy-in-metastatic-oligoprogressive-lung-cancer-international-journal-of-molecular-sc\/\">Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer &#8211; INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Zafra, J; Onieva, JL; Oliver, J; Garrido-Barros, M; Gonz\u00e1lez-Hern\u00e1ndez, A; Mart\u00ednez-G\u00e1lvez, B; Rom\u00e1n, A; Ord\u00f3\u00f1ez-Marmolejo, R; P\u00e9rez-Ruiz, E; Ben\u00edtez, JC; Mesas, A; Vera, A; Chicas-Sett, R; Rueda-Dom\u00ednguez, A; Barrag\u00e1n, I &#8211; 2024 &#8211; 10.3390\/ijms25084533<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52186\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_5 post-52186 post type-post status-publish format-standard hentry category-publicaciones-b-01 category-publicaciones-b-05 category-publicaciones-b-22 category-publicaciones-be-23\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/oncogene-addicted-solid-tumors-and-microbiome-lung-cancer-as-a-main-character-a-narrative-review-translational-lung-cancer-research\/\">Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review &#8211; TRANSLATIONAL LUNG CANCER RESEARCH<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Guardamagna, M; Meyer, ML; Berciano-Guerrero, MA; Mesas-Ruiz, A; Cobo-Dols, M; Perez-Ruiz, E; Gonzalez, AC; Lavado-Valenzuela, R; Barrag\u00e1n, I; Oliver, J; Garrido-Aranda, A; Alvarez, M; Rueda-Dominguez, A; Queipo-Ortu\u00f1o, MI; Conejo, EA; Benitez, JC &#8211; 2024 &#8211; 10.21037\/tlcr-24-216<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52246\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_6 post-52246 post type-post status-publish format-standard hentry category-publicaciones-b-05 category-publicaciones-b-10 category-publicaciones-c-14\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/positive-impact-of-distintivo-soludable-on-implementation-of-sun-protection-policies-and-practices-in-schools-of-andalusia-spain-journal-of-public-health-policy\/\">Positive impact of Distintivo Soludable on implementation of sun protection policies and practices in schools of Andalusia, Spain &#8211; JOURNAL OF PUBLIC HEALTH POLICY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Garc\u00eda-Harana, C; Bl\u00e1zquez-S\u00e1nchez, N; Rodr\u00edguez-Mart\u00ednez, A; Rivas-Ruiz, F; Aguilar-Ortega, D; Rodr\u00edguez-Mart\u00ednez, AG; Cambil-Mart\u00edn, J; de G\u00e1lvez, MV; de Troya-Mart\u00edn, M &#8211; 2024 &#8211; 10.1057\/s41271-024-00495-0<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51630\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_7 post-51630 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/comparative-study-between-the-diagnostic-effectiveness-of-brain-spect-with-123iioflupane-and-123imibg-scintigraphy-in-multiple-system-atrophy-biomedicines\/\">Comparative Study between the Diagnostic Effectiveness of Brain SPECT with [123I]Ioflupane and [123I]MIBG Scintigraphy in Multiple System Atrophy &#8211; BIOMEDICINES<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Villena-Salinas, J; Ortega-Lozano, SJ; Amrani-Raissouni, T; Ag\u00fcera-Morales, E; Caballero-Villarraso, J &#8211; 2024 &#8211; 10.3390\/biomedicines12010102<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52357\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_8 post-52357 post type-post status-publish format-standard hentry category-publicaciones-b-01 category-publicaciones-b-05 category-publicaciones-b-22\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/role-of-poly-adp-ribose-polymerase-inhibitors-after-brain-progression-in-platinum-sensitive-ovarian-cancer-a-case-report-and-review-of-the-literature-frontiers-in-oncology\/\">Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature &#8211; FRONTIERS IN ONCOLOGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Lendinez-Sanchez, G; Diaz-Redondo, T; Iglesias-Campos, M; Garrido-Almaz\u00e1n, L; Alba-Conejo, E; Rueda-Dominguez, A; Sanchez-Mu\u00f1oz, A &#8211; 2024 &#8211; 10.3389\/fonc.2024.1423992<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51660\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_9 post-51660 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/current-challenges-in-the-treatment-of-gliomas-the-molecular-era-world-journal-of-clinical-oncology\/\">Current challenges in the treatment of gliomas: The molecular era &#8211; WORLD JOURNAL OF CLINICAL ONCOLOGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Fern\u00e1ndez, C; Zafra-Mart\u00edn, J; Cou\u00f1ago, F &#8211; 2024 &#8211; 10.5306\/wjco.v15.i8.982<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52375\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_10 post-52375 post type-post status-publish format-standard hentry category-publicaciones-b-05 category-publicaciones-fe-20\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/sentinel-lymph-node-biopsy-after-neoadjuvant-chemotherapy-in-cn0-breast-cancer-impact-of-her2-positive-status-on-survival-european-journal-of-breast-health\/\">Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in cN0 Breast Cancer: Impact of HER2-Positive Status on Survival &#8211; EUROPEAN JOURNAL OF BREAST HEALTH<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Alors-Ruiz, J; Sanz-Viedma, S; Fernandez-Garcia, FJ; Sendra-Portero, F &#8211; 2024 &#8211; 10.4274\/ejbh.galenos.2024.2023-11-3<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51717\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_11 post-51717 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/divarasib-plus-cetuximab-in-krasg12c-positive-colorectal-cancer-a-phase-1b-trial-nature-medicine\/\">Divarasib plus cetuximab in KRASG12C-positive colorectal cancer: a phase 1b trial &#8211; NATURE MEDICINE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Desai, J; Alonso, G; Kim, SH; Cervantes, A; Karasic, T; Medina, L; Shacham-Shmueli, E; Cosman, R; Falcon, A; Gore, E; Guren, T; Massarelli, E; Jr, WHM; Paz-Ares, L; Prenen, H; Amatu, A; Cremolini, C; Kim, TW; Moreno, V; Ou, SH; Passardi, A; Sacher, A; Santoro, A; Stec, R; Ulahannan, S; Arbour, K; Lorusso, P; Luo, J; Patel, MR; Choi, Y; Shi, Z; Mandlekar, S; Lin, MT; Royer-Joo, S; Chang, J; Jun, T; Dharia, N; Schutzman, JL; Han, SW &#8211; 2024 &#8211; 10.1038\/s41591-023-02696-8<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52398\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_12 post-52398 post type-post status-publish format-standard hentry category-publicaciones-b-05 category-publicaciones-b-10 category-publicaciones-c-14\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/skin-cancer-prevention-in-extreme-sports-intervention-in-a-24-h-race-photodermatology-photoimmunology-photomedicine\/\">Skin cancer prevention in extreme sports: Intervention in a 24-h race &#8211; PHOTODERMATOLOGY PHOTOIMMUNOLOGY &#038; PHOTOMEDICINE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Mart\u00ednez, AR; Pardal, CV; Arjona, JA; Ruiz, FR; Molinero, DD; Paulano, MR; Subert, A; Guti\u00e9rrez-Manzanedo, JV; Mart\u00edn, JC; Aranda, MVD; L\u00f3pez, LJ; S\u00e1nchez, NB; Mart\u00edn, MD &#8211; 2024 &#8211; 10.1111\/phpp.12940<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51818\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_13 post-51818 post type-post status-publish format-standard hentry category-publicaciones-b-05 category-publicaciones-be-21 category-publicaciones-d-04\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/epigenetic-targets-to-enhance-antitumor-immune-response-through-the-induction-of-tertiary-lymphoid-structures-frontiers-in-immunology-2\/\">Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures &#8211; FRONTIERS IN IMMUNOLOGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Omotesho, QA; Escamilla, A; Perez-Ruiz, E; Frecha, CA; Rueda-Dominguez, A; Barragan, I &#8211; 2024 &#8211; 10.3389\/fimmu.2024.1348156<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52504\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_14 post-52504 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/total-neoadjuvant-therapy-approach-for-the-treatment-of-locally-advanced-rectal-cancer-where-do-we-stand-oncology\/\">Total neoadjuvant therapy approach for the treatment of locally advanced rectal cancer. Where do we stand? &#8211; ONCOLOGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Zoghbi, SER; Mart\u00edn, MM; Garc\u00eda, JC; Valero, M; Rinc\u00f3n, D; Huertas, MP; Fusco, JP; L\u00f3pez, E; Zafra, J; Luengas, DF; Campos, FL; Cou\u00f1ago, F &#8211; 2024 &#8211; 10.1159\/000534888<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51859\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_15 post-51859 post type-post status-publish format-standard hentry category-publicaciones-b-05 category-publicaciones-fe-20\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/false-positive-in-99mtctc-dpd-scintigraphy-for-cardiac-amyloidosis-due-to-intravenous-iron-administration-clinical-nuclear-medicine\/\">False Positive in [99mTc]Tc-DPD Scintigraphy for Cardiac Amyloidosis Due to Intravenous Iron Administration &#8211; CLINICAL NUCLEAR MEDICINE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Solero, TR; Arag\u00f3n, MF; Raissouni, TA; Delgado-Garc\u00eda, A; Ca\u00f1ada-Rodr\u00edguez, MJ; Viedma, SS &#8211; 2024 &#8211; 10.1097\/RLU.0000000000004981<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51925\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_16 post-51925 post type-post status-publish format-standard hentry category-publicaciones-b-01 category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/hodgkin-lymphoma-and-liquid-biopsy-a-story-to-be-told-journal-of-experimental-clinical-cancer-research\/\">Hodgkin lymphoma and liquid biopsy: a story to be told &#8211; JOURNAL OF EXPERIMENTAL &#038; CLINICAL CANCER RESEARCH<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Velasco-Suelto, J; G\u00e1lvez-Carvajal, L; Comino-M\u00e9ndez, I; Rueda-Dom\u00ednguez, A &#8211; 2024 &#8211; 10.1186\/s13046-024-03108-6<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51951\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_17 post-51951 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/impact-of-a-glutamine-enriched-peptide-formula-on-gastrointestinal-toxicity-and-on-the-interruption-of-oncologic-treatment-in-patients-with-adenocarcinoma-of-the-rectum-frontiers-in-nutrition\/\">Impact of a glutamine-enriched peptide formula on gastrointestinal toxicity and on the interruption of oncologic treatment in patients with adenocarcinoma of the rectum &#8211; FRONTIERS IN NUTRITION<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Salas-Salas, BG; Ferrera-Alay\u00f3n, L; Calleja-Fern\u00e1ndez, A; Chicas-Sett, R; Nogu\u00e9s-Ramia, E; Zafra-Mart\u00edn, J; Lloret, M &#8211; 2024 &#8211; 10.3389\/fnut.2024.1414367<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51990\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_18 post-51990 post type-post status-publish format-standard hentry category-publicaciones-b-01 category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/increasing-annual-cancer-incidence-in-patients-age-20-49-years-a-real-data-study-jco-global-oncology\/\">Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study &#8211; JCO GLOBAL ONCOLOGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Ribelles, N; Pascual, J; Galvez-Carvajal, L; Ruiz-Medina, S; Garcia-Corbacho, J; Benitez, JC; Dominguez-Recio, ME; Torres, E; Oliva, L; Zalabardo, M; Rueda, A; Alba, E &#8211; 2024 &#8211; 10.1200\/GO.23.00363<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51994\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_19 post-51994 post type-post status-publish format-standard hentry category-publicaciones-b-05\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/indicators-to-evaluate-quality-of-care-in-head-and-neck-cancer-in-spain-clinical-translational-oncology\/\">Indicators to evaluate quality of care in head and neck cancer in Spain &#8211; CLINICAL &#038; TRANSLATIONAL ONCOLOGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Hern\u00e1ndez, JJC; Arrula, VA; Alvarez, YE; Casta\u00f1o, AG; de Castro, JJG; Docampo, LI; Sorrosal, JL; Segura, PP; Dom\u00ednguez, AR; Campos-Lucas, FJ; Rodr\u00edguez, IS; Bessa, M; Gratal, P; Caballero-Mart\u00ednez, F; Mart\u00edn, DM; Ant\u00f3n-Rodr\u00edguez, C; L\u00f3pez, R &#8211; 2024 &#8211; 10.1007\/s12094-023-03298-z<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div><div><div class=\"pagination clearfix\">\n\t<div class=\"alignleft\"><a href=\"https:\/\/ibima.eu\/wp-json\/wp\/v2\/project\/26532\/page\/2\/?et_blog\" >&laquo; Older Entries<\/a><\/div>\n\t<div class=\"alignright\"><\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div><div class=\"et_pb_section et_pb_section_4 et_section_regular\" >\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_row et_pb_row_0\">\n\t\t\t\t<div class=\"et_pb_column et_pb_column_4_4 et_pb_column_0  et_pb_css_mix_blend_mode_passthrough et-last-child\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module et_pb_blog_3 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix \">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"et_pb_salvattore_content\" data-columns>\n\t\t\t<article id=\"post-57255\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_3_0 post-57255 post type-post status-publish format-standard hentry category-dispositivos-medicos category-grupo-de-investigacion-b-05 category-ofertas-tecnologicas tag-dispositivo-medico tag-infusion tag-radiofarmaco\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/dispositivo-de-sujecion-para-dar-soporte-a-una-jeringa-radiofarmaco\/\">Dispositivo de sujeci\u00f3n para dar soporte a una jeringa radiof\u00e1rmaco<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_multi_view_hidden\"><\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-38145\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_3_1 post-38145 post type-post status-publish format-standard hentry category-diagnostico category-grupo-de-investigacion-b-05 category-grupo-de-investigacion-b-01 category-ofertas-tecnologicas tag-biomarcador tag-cancer tag-inmunoterapia tag-melanoma tag-pronostico\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/metodo-para-predecir-la-respuesta-a-inmunoterapia-en-pacientes-con-melanoma-cutaneo\/\">M\u00e9todo para predecir la respuesta a inmunoterapia en pacientes con melanoma cut\u00e1neo.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_multi_view_hidden\"><\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-36636\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_3_2 post-36636 post type-post status-publish format-standard hentry category-diagnostico category-grupo-de-investigacion-b-05 category-grupo-de-investigacion-b-14 category-ofertas-tecnologicas tag-covid tag-marcador tag-pronostico\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/biomarcador-de-pronostico-en-pacientes-covid-19\/\">Biomarcador de pron\u00f3stico en pacientes COVID-19<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_multi_view_hidden\"><\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-36446\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_3_3 post-36446 post type-post status-publish format-standard hentry category-diagnostico category-grupo-de-investigacion-b-05 category-grupo-de-investigacion-b-01 category-ofertas-tecnologicas tag-inmunoterapia tag-melanoma tag-oncologia\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/metodo-para-predecir-la-respuesta-del-cancer-al-tratamiento-con-inmunoterapia-con-anti-pd1\/\">M\u00e9todo para predecir la respuesta del c\u00e1ncer al tratamiento con inmunoterapia con anti-PD1.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_multi_view_hidden\"><\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div> \n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div><div class=\"et_pb_module dsm_icon_list dsm_icon_list_0\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module_inner\">\n\t\t\t\t\t<ul class=\"dsm_icon_list_items dsm_icon_list_ltr_direction dsm_icon_list_layout_vertical\"><\/ul>\n\t\t\t\t<\/div>\n\t\t\t<\/div><div class=\"et_pb_module dsm_icon_list dsm_icon_list_1\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module_inner\">\n\t\t\t\t\t<ul class=\"dsm_icon_list_items dsm_icon_list_ltr_direction dsm_icon_list_layout_vertical\"><\/ul>\n\t\t\t\t<\/div>\n\t\t\t<\/div><li class=\"dsm_icon_list_child dsm_icon_list_child_0 dsm_icon_list_child_tooltip\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"dsm_icon_list_tooltip\" data-tippy-arrow=\"true\" data-tippy-placement=\"top\" data-dsm-slug=\"dsm_icon_list_child_0\"><span class=\"dsm_icon_list_wrapper\"><\/span><span class=\"dsm_icon_list_text\">Investigador Responsable<\/span><\/div>\n\t\t\t<\/li>Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section fb_built=\"1\" _builder_version=\"4.20.4\" _module_preset=\"default\" background_image=\"https:\/\/ibima.eu\/wp-content\/uploads\/2023\/04\/FotoWeb-min-1000x500-1.jpg\" global_colors_info=\"{}\"][et_pb_row _builder_version=\"4.20.4\" _module_preset=\"default\" custom_padding=\"250px||30px||false|false\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.20.4\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.23.1\" _module_preset=\"default\" header_font=\"Poppins|700|||||||\" header_text_align=\"center\" header_text_color=\"#FFFFFF\" header_font_size=\"40px\" header_2_font=\"Poppins|700|||||||\" header_2_text_color=\"#FFFFFF\" header_2_font_size=\"46px\" global_colors_info=\"{}\"]<h1>Endocrinolog\u00eda y Nutrici\u00f3n, Diabetes y Obesidad<\/h1>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" _builder_version=\"4.20.4\" _module_preset=\"default\" background_color=\"#235b78\" custom_padding=\"30px||30px||true|false\" global_colors_info=\"{}\"][et_pb_row _builder_version=\"4.20.4\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.20.4\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.23.1\" _module_preset=\"default\" header_3_font=\"Poppins|700|||||||\" header_3_text_color=\"#FFFFFF\" header_3_font_size=\"34px\" global_colors_info=\"{}\"]<h3>Lineas de Investigaci\u00f3n<\/h3>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" _builder_version=\"4.20.4\" _module_preset=\"default\" background_color=\"#d3d6dd\" custom_margin=\"||||true|false\" custom_padding=\"50px||50px||true|false\" global_colors_info=\"{}\"][et_pb_row use_custom_gutter=\"on\" gutter_width=\"2\" _builder_version=\"4.20.4\" _module_preset=\"default\" width=\"70%\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.20.4\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.23.1\" _module_preset=\"default\" text_text_color=\"#235b78\" text_font_size=\"16px\" text_line_height=\"2.1em\" global_colors_info=\"{}\"]<p><span style=\"color: #43a5d3;\"><strong>01.<\/strong><\/span>Obesidad y diabetes traslacional: metabolismo del tejido adiposo y de la c\u00e9lula beta<br \/><span style=\"color: #43a5d3;\"><strong>02.<\/strong><\/span>Nuevas aproximaciones en investigaci\u00f3n cl\u00ednica-experimental en siabetes y metabolismo y nutrici\u00f3n cl\u00ednica aplicada a enfermedades cr\u00f3nicas.<br \/><span style=\"color: #43a5d3;\"><strong>03.<\/strong><\/span>Epidemiolog\u00eda y factores de riesgo de diabetes y enfermedades metab\u00f3licas relacionadas<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" _builder_version=\"4.20.4\" _module_preset=\"default\" custom_padding=\"50px||50px||true|false\" global_colors_info=\"{}\"][et_pb_row column_structure=\"2_3,1_3\" use_custom_gutter=\"on\" gutter_width=\"2\" make_equal=\"on\" _builder_version=\"4.20.4\" _module_preset=\"default\" width=\"90%\" global_colors_info=\"{}\"][et_pb_column type=\"2_3\" _builder_version=\"4.20.4\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_tabs active_tab_background_color=\"#105e7c\" inactive_tab_background_color=\"#41a7d4\" active_tab_text_color=\"#FFFFFF\" _builder_version=\"4.24.0\" _module_preset=\"default\" tab_text_color=\"#FFFFFF\" hover_enabled=\"0\" border_color_all=\"#41a7d4\" global_colors_info=\"{}\" sticky_enabled=\"0\"][et_pb_tab title=\"Proyectos de investigaci\u00f3n\" _builder_version=\"4.24.0\" _module_preset=\"default\" hover_enabled=\"0\" global_colors_info=\"{}\" sticky_enabled=\"0\"]<p>[divi_shortcode id=\"26508\"]<\/p>\n<div id=\"gtx-trans\" style=\"position: absolute; left: 190px; top: -10px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>[\/et_pb_tab][et_pb_tab title=\"Estudios cl\u00ednicos\" _builder_version=\"4.24.0\" _module_preset=\"default\" hover_enabled=\"0\" global_colors_info=\"{}\" sticky_enabled=\"0\"]<p>[divi_shortcode id=\"26514\"]<\/p>[\/et_pb_tab][et_pb_tab title=\"Publicaciones cient\u00edficas\" _builder_version=\"4.24.0\" _module_preset=\"default\" hover_enabled=\"0\" global_colors_info=\"{}\" sticky_enabled=\"0\"]<p>[divi_shortcode id=\"26511\"]<\/p>[\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][et_pb_column type=\"1_3\" _builder_version=\"4.20.4\" _module_preset=\"default\" border_width_left=\"1px\" border_color_left=\"rgba(67,165,211,0.32)\" global_colors_info=\"{}\"][et_pb_blurb title=\"Miembros\" use_icon=\"on\" font_icon=\"&#xf0c0;||fa||900\" icon_color=\"#43a5d3\" icon_placement=\"left\" _builder_version=\"4.23.1\" _module_preset=\"default\" header_font=\"Poppins|600|||||||\" header_text_color=\"#235b78\" header_font_size=\"22px\" module_alignment=\"center\" custom_margin=\"||||false|false\" custom_padding=\"|||80px|false|false\" global_colors_info=\"{}\"][\/et_pb_blurb][et_pb_divider color=\"#43a5d3\" divider_weight=\"2px\" _builder_version=\"4.23.1\" _module_preset=\"default\" width=\"70%\" custom_padding=\"|||80px|false|false\" global_colors_info=\"{}\"][\/et_pb_divider][dsm_icon_list _builder_version=\"4.23.1\" _module_preset=\"default\" custom_margin=\"|||80px|false|false\" global_colors_info=\"{}\"][\/dsm_icon_list][et_pb_blurb title=\" Gabriel Olveira Fuster\" image=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/01\/A-01-Gabriel-Olveira.png\" icon_placement=\"left\" image_icon_width=\"71px\" content_max_width=\"558px\" _builder_version=\"4.24.0\" _module_preset=\"default\" header_font=\"Poppins||||||||\" header_text_color=\"#24a8d7\" body_link_text_color=\"#919191\" custom_padding=\"|||80px|false|false\" border_radii_image=\"on|25%|25%|25%|25%\" global_colors_info=\"{}\"]<p><strong>Correo electr\u00f3nico:<\/strong> <a href=\"mailto:gabrielm.olveira.sspa@juntadeandalucia.es\">gabrielm.olveira.sspa@juntadeandalucia.es<\/a><br \/><a href=\"https:\/\/orcid.org\/0000-0002-7646-2899\" target=\"_blank\" rel=\"noopener\"><strong>ORCID<\/strong><\/a><br \/><a href=\"https:\/\/www.scopus.com\/authid\/detail.uri?authorId=6602924630\" target=\"_blank\" rel=\"noopener\"><strong>SCOPUS<\/strong><\/a><\/p>[\/et_pb_blurb][dsm_icon_list _builder_version=\"4.23.1\" _module_preset=\"default\" custom_margin=\"|||80px|false|false\" global_colors_info=\"{}\"][\/dsm_icon_list][et_pb_blurb title=\"Javier Berm\u00fadez Silva\" image=\"https:\/\/ibima.eu\/wp-content\/uploads\/2023\/05\/person-icon-1.png\" icon_placement=\"left\" _builder_version=\"4.24.0\" _module_preset=\"default\" header_font=\"Poppins||||||||\" header_text_color=\"#24a8d7\" body_link_text_color=\"#919191\" custom_padding=\"|||80px|false|false\" global_colors_info=\"{}\"]<p><strong>Correo electr\u00f3nico:<\/strong> <a href=\"mailto:javier.bermudez@ibima.eu\">javier.bermudez@ibima.eu<\/a><br \/><a href=\"https:\/\/orcid.org\/0000-0003-3133-9691\" target=\"_blank\" rel=\"noopener\"><strong>ORCID<\/strong><\/a><br \/><a href=\"https:\/\/www.scopus.com\/authid\/detail.uri?authorId=8628804500\" target=\"_blank\" rel=\"noopener\"><strong>SCOPUS<\/strong><\/a><\/p>[\/et_pb_blurb][dsm_icon_list _builder_version=\"4.23.1\" _module_preset=\"default\" custom_margin=\"|||80px|false|false\" global_colors_info=\"{}\"][\/dsm_icon_list][et_pb_blog posts_number=\"20\" include_categories=\"1673\" show_thumbnail=\"off\" show_content=\"on\" show_author=\"off\" show_date=\"off\" show_categories=\"off\" _builder_version=\"4.23.4\" _module_preset=\"default\" header_font=\"Poppins|600|||||||\" header_text_color=\"#41a7d4\" header_font_size=\"16px\" body_text_color=\"#105e7c\" body_font_size=\"12px\" custom_padding=\"|||100px|false|false\" global_colors_info=\"{}\"][\/et_pb_blog][dsm_icon_list _builder_version=\"4.23.1\" _module_preset=\"default\" custom_margin=\"|||80px|false|false\" global_colors_info=\"{}\"][\/dsm_icon_list][et_pb_blog posts_number=\"20\" include_categories=\"1668\" show_thumbnail=\"off\" show_content=\"on\" show_author=\"off\" show_date=\"off\" show_categories=\"off\" _builder_version=\"4.23.4\" _module_preset=\"default\" header_font=\"Poppins|600|||||||\" header_text_color=\"#41a7d4\" header_font_size=\"16px\" body_text_color=\"#105e7c\" body_font_size=\"12px\" custom_padding=\"|||100px|false|false\" locked=\"off\" global_colors_info=\"{}\"][\/et_pb_blog][dsm_icon_list _builder_version=\"4.23.1\" _module_preset=\"default\" custom_margin=\"|||80px|false|false\" global_colors_info=\"{}\"][\/dsm_icon_list][et_pb_blog posts_number=\"20\" include_categories=\"1670\" show_thumbnail=\"off\" show_content=\"on\" show_author=\"off\" show_date=\"off\" show_categories=\"off\" _builder_version=\"4.23.4\" _module_preset=\"default\" header_font=\"Poppins|600|||||||\" header_text_color=\"#41a7d4\" header_font_size=\"16px\" body_text_color=\"#105e7c\" body_font_size=\"12px\" custom_padding=\"|||100px|false|false\" global_colors_info=\"{}\"][\/et_pb_blog][dsm_icon_list _builder_version=\"4.23.1\" _module_preset=\"default\" custom_margin=\"|||80px|false|false\" global_colors_info=\"{}\"][\/dsm_icon_list][et_pb_blog posts_number=\"20\" include_categories=\"1669\" show_thumbnail=\"off\" show_content=\"on\" show_author=\"off\" show_date=\"off\" show_categories=\"off\" _builder_version=\"4.23.4\" _module_preset=\"default\" header_font=\"Poppins|600|||||||\" header_text_color=\"#41a7d4\" header_font_size=\"16px\" body_text_color=\"#105e7c\" body_font_size=\"12px\" custom_padding=\"|||100px|false|false\" global_colors_info=\"{}\"][\/et_pb_blog][dsm_icon_list _builder_version=\"4.23.1\" _module_preset=\"default\" custom_margin=\"|||80px|false|false\" global_colors_info=\"{}\"][\/dsm_icon_list][et_pb_blog posts_number=\"20\" include_categories=\"1671\" show_thumbnail=\"off\" show_content=\"on\" show_author=\"off\" show_date=\"off\" show_categories=\"off\" _builder_version=\"4.23.4\" _module_preset=\"default\" header_font=\"Poppins|600|||||||\" header_text_color=\"#41a7d4\" header_font_size=\"16px\" body_text_color=\"#105e7c\" body_font_size=\"12px\" custom_padding=\"|||100px|false|false\" global_colors_info=\"{}\"][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":"","footnotes":""},"project_category":[2052],"project_tag":[],"class_list":["post-26532","project","type-project","status-publish","hentry","project_category-pruebacategoria2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>B-05 - Ibima<\/title>\n<meta name=\"description\" content=\"El grupo de investigaci\u00f3n consolidado B-05 se dedica a la investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9tica\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/project\/b-05\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"B-05 - Ibima\" \/>\n<meta property=\"og:description\" content=\"El grupo de investigaci\u00f3n consolidado B-05 se dedica a la investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9tica\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/project\/b-05\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T13:09:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/project\\\/b-05\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/project\\\/b-05\\\/\",\"name\":\"B-05 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2024-01-31T11:32:17+00:00\",\"dateModified\":\"2025-11-25T13:09:16+00:00\",\"description\":\"El grupo de investigaci\u00f3n consolidado B-05 se dedica a la investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9tica\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/project\\\/b-05\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/project\\\/b-05\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/project\\\/b-05\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Proyectos\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"B-05\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"B-05 - Ibima","description":"El grupo de investigaci\u00f3n consolidado B-05 se dedica a la investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9tica","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/project\/b-05\/","og_locale":"en_GB","og_type":"article","og_title":"B-05 - Ibima","og_description":"El grupo de investigaci\u00f3n consolidado B-05 se dedica a la investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9tica","og_url":"https:\/\/ibima.eu\/en\/project\/b-05\/","og_site_name":"Ibima","article_modified_time":"2025-11-25T13:09:16+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/project\/b-05\/","url":"https:\/\/ibima.eu\/project\/b-05\/","name":"B-05 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2024-01-31T11:32:17+00:00","dateModified":"2025-11-25T13:09:16+00:00","description":"El grupo de investigaci\u00f3n consolidado B-05 se dedica a la investigaci\u00f3n Traslacional en Inmunoterapia del C\u00e1ncer y Epigen\u00e9tica","breadcrumb":{"@id":"https:\/\/ibima.eu\/project\/b-05\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/project\/b-05\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/project\/b-05\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Proyectos","item":"https:\/\/ibima.eu\/es\/project\/"},{"@type":"ListItem","position":3,"name":"B-05"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/26532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=26532"}],"version-history":[{"count":8,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/26532\/revisions"}],"predecessor-version":[{"id":58580,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/26532\/revisions\/58580"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=26532"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project_category?post=26532"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project_tag?post=26532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}